Pancreas News and Research

RSS

The pancreas is a gland organ in the digestive and endocrine system of vertebrates. It is both an endocrine gland producing several important hormones, including insulin, glucagon, and somatostatin, as well as an exocrine gland, secreting pancreatic juice containing digestive enzymes that pass to the small intestine. These enzymes help in the further breakdown of the carbohydrates, protein, and fat in the chyme.

Boosting levels of ABCG1 protein in diabetics will improve insulin production

If you think of diabetes onset like an elaborate molecular drama, then a research team led by a La Jolla Institute scientist has unmasked a previously unknown cellular player, which is critical to proper insulin secretion. "Defective insulin secretion is a hallmark of both type 1 and type 2 diabetes," said Catherine Hedrick, Ph.D., a scientist at the La Jolla Institute for Allergy & Immunology, who led the team, which included researchers from the University of Virginia.

8 Jun 2010

La Jolla Institute scientist finds protein key to insulin secretion

8 Jun 2010

NewLink Genetics reports positive data from Phase 2 trial of HyperAcute-Pancreas cancer immunotherapy

NewLink Genetics Corporation today announced positive Phase 2 clinical trial data of its HyperAcute®-Pancreas cancer immunotherapy combined with standard adjuvant chemotherapy in patients with surgically resectable pancreatic cancer. The study results suggest a potentially longer disease-free survival and one-year overall survival in this patient group than reported in previous studies of surgery and adjuvant therapy alone. These data were presented in a poster session at the American Society of Clinical Oncology (ASCO) annual meeting.

7 Jun 2010

New clinical research findings on oncology to be highlighted at ASCO 2010

Researchers from University Hospitals Case Medical Center's Ireland Cancer Center will present new clinical research findings at the 46th Annual Meeting of The American Society of Clinical Oncology June 4-8 in Chicago.

5 Jun 2010

Montefiore-Einstein announces Abdominal Organ Transplant Symposium on June 10, 2010

The Montefiore-Einstein Abdominal Organ Transplantation Service will hold an Abdominal Organ Transplant Symposium on Thursday, June 10, 2010 from 7:30 am - 4:30 pm at the Moses Division of Montefiore Medical Center on Gun Hill Road in the Bronx, NY.

4 Jun 2010

Researchers find a way to isolate pancreatic islet cells from brain dead donors using DI

A team of researchers from several collaborating Baylor University research centers and from Japan's Okayama Graduate School of Medicine have found a way to more consistently isolate pancreatic islet cells from brain dead donors using ductal injection, a process that immediately cools donor islet cells at the injection site.

4 Jun 2010

Early detection and removal of pancreatic cysts may lower cancer risk: Researchers

Working with researchers from the University of Michigan and Indiana University, Van Andel Research Institute investigators have developed a method that could be used to predict whether pancreatic cysts are benign or are precursors to invasive cancer.

4 Jun 2010

Postdoctoral scientists receive NYSCF-Druckenmiller Fellowship award

The New York Stem Cell Foundation (NYSCF) today announced the award of eight new NYSCF-Druckenmiller Fellows. These postdoctoral scientists join 15 accomplished stem cell researchers from leading institutions who have been supported by the program since 2006. NYSCF has awarded 23 fellowships to date.

2 Jun 2010

Major response to preoperative therapy increases survival in pancreatic cancer patients

Cancer of the pancreas--a glandular organ that lies behind the stomach and secretes vital enzymes and hormones--seldom is detected in early stages, making treatment difficult and survival statistics particularly grim. However, new research from Fox Chase Cancer Center finds that patients with pancreatic adenocarcinoma whose tumors respond most to preoperative chemotherapy and radiation survive four times as long, on average, as those whose tumors respond least.

29 May 2010

FDA, EMA approve Repligen's proposal for Phase 3 re-read in RG1068 trial for pancreatic imaging

Repligen Corporation announced today that the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved the Company's proposal to re-analyze the images from our Phase 3 study to establish the utility of RG1068, synthetic human secretin, in improving magnetic resonance imaging (MRI) of the pancreas (Phase 3 re-read).

27 May 2010

Data evaluating use of nab-paclitaxel for treatment of pancreatic cancer to be presented at ASCO 2010

Abraxis BioScience, Inc., a fully integrated biotechnology company, previously announced it will be presenting more than 30 studies, including new clinical data evaluating the use of nanoparticle albumin bound driven chemotherapy, nab-paclitaxel (ABRAXANE for Injectable suspension; paclitaxel protein albumin-bound particles for injectable suspension) for the treatment of pancreatic cancer at the 46th Annual Meeting of the American Society of Clinical Oncology in Chicago.

21 May 2010

NewLink Genetics to present Phase 2 data of HyperAcute-Pancreas immunotherapy for resected pancreatic cancer

NewLink Genetics Corporation today announced that preliminary data from its Phase 2 clinical trial evaluating the effect of HyperAcute®-Pancreas immunotherapy in patients with resected pancreatic cancer will be presented during a poster session at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting held June 4-8, 2010 in Chicago, Illinois. A summary of the company's ASCO presentation is below.

20 May 2010

Recruitment of children and adults with type 1 diabetes commences in Protege Encore teplizumab trial

Dr. Barry Reiner announced that he is now recruiting children and adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes. There is currently no approved therapy to slow the progression of type 1 diabetes.

20 May 2010

Adults with newly diagnosed type 1 diabetes recruited for Protege Encore clinical trial

Dr. Bruce Bode announced today that he is now recruiting adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes.

18 May 2010

BioSante Pharmaceuticals first-quarter net loss increases to $10.5 million

BioSante Pharmaceuticals, Inc. today reported on its recent developments and financial results for the first quarter, and its cash balance as of March 31, 2010.

14 May 2010

New cases of Type 1 diabetes in young children to double by 2020: The Lancet

By 2020, new cases of Type 1 diabetes in children younger than five are expected to double if current trends continue, according to a study published in The Lancet. Diabetes is an epidemic, with numbers of those suffering from diabetes and its complications increasing worldwide.

14 May 2010

RYGB surgery increases insulin activity in diabetes mellitus patients

Diabetes mellitus is a chronic metabolic disease resulted from, either decreased production of insulin or increased resistance to it from peripheral tissues or both factors combined together. While medical treatment remains the mainstay of treatment for diabetes, some surgical procedures, such as Roux-en-Y gastric bypass, have demonstrated some potential to be a treatment option for diabetes.

13 May 2010

People with family history of diabetes gain more weight

In the first study of its type, Australian researchers have shown that healthy people with a genetic predisposition to Type 2 diabetes gain more weight overeating over the short term than their non-genetically-prone counterparts.

11 May 2010

Findings may help develop a new class of drugs for diabetes

More than half a century after researchers identified a promising way to treat diabetes based on blocking the breakdown of insulin in the body, a research team led by a scientist at the Mayo Clinic campus in Florida have developed potent molecules that can do just that.

10 May 2010

MBPs offer no clinical benefit to patients undergoing PD: Research team

Mechanical bowel preparations are commonly administered preoperatively to patients who undergo a pancreaticoduodenectomy (Whipple procedure) to treat benign and malignant tumors of the pancreas, common bile duct or duodenum. MBPs are employed as a preventative measure in gastrointestinal surgery but their effectiveness in reducing perioperative infectious complications remains unclear.

7 May 2010

Pancreas News and Research

Further Reading

Boosting levels of ABCG1 protein in diabetics will improve insulin production

La Jolla Institute scientist finds protein key to insulin secretion

NewLink Genetics reports positive data from Phase 2 trial of HyperAcute-Pancreas cancer immunotherapy

New clinical research findings on oncology to be highlighted at ASCO 2010

Montefiore-Einstein announces Abdominal Organ Transplant Symposium on June 10, 2010

Researchers find a way to isolate pancreatic islet cells from brain dead donors using DI

Early detection and removal of pancreatic cysts may lower cancer risk: Researchers

Postdoctoral scientists receive NYSCF-Druckenmiller Fellowship award

Major response to preoperative therapy increases survival in pancreatic cancer patients

FDA, EMA approve Repligen's proposal for Phase 3 re-read in RG1068 trial for pancreatic imaging

Data evaluating use of nab-paclitaxel for treatment of pancreatic cancer to be presented at ASCO 2010

NewLink Genetics to present Phase 2 data of HyperAcute-Pancreas immunotherapy for resected pancreatic cancer

Recruitment of children and adults with type 1 diabetes commences in Protege Encore teplizumab trial

Adults with newly diagnosed type 1 diabetes recruited for Protege Encore clinical trial

BioSante Pharmaceuticals first-quarter net loss increases to $10.5 million

New cases of Type 1 diabetes in young children to double by 2020: The Lancet

RYGB surgery increases insulin activity in diabetes mellitus patients

People with family history of diabetes gain more weight

Findings may help develop a new class of drugs for diabetes

MBPs offer no clinical benefit to patients undergoing PD: Research team

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News